Despite huge efforts to understand the molecular mechanisms underpinning cancer drug resistance and identify new therapeutic targets, pre-clinical findings often show limited translation into the clinic where many patients do not respond well to such treatments. The main limitation of standard pre-clinical cancer model systems, such as mono-layer cellular cultures or animal models, is the inability to reflect the intra- and inter-tumoral heterogeneity and tumor microenvironment, accepted to be major components in cancer development.
The need for pre-clinical tools that better predict the individual clinical outcome has led to the development of innovative patient-derived models. Among this new class of pre-clinical models, patient-derived xenografts (PDXs) and patient-derived organoids (PDOs) have shown great potential for guiding personalized cancer therapies as they preserve the primary molecular features exhibited in tumors.
In this Research Topic, we welcome contributions that provide original insights, novel reviews, and critical perspectives focused on, but not limited to:
- the latest developments in PDXs and PDOs as pre-clinical models
- the incorporation of cellular microenvironment in PDOs and generation of syngeneic models
- the use of PDXs and PDOs to develop and improve cancer treatments
- the ability of PDXs and PDOs models to predict the individualized treatment response
- the use of PDXs and PDOs models to study drug resistance
- the advances in the translation of PDXs and PDOs models into the clinics
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Despite huge efforts to understand the molecular mechanisms underpinning cancer drug resistance and identify new therapeutic targets, pre-clinical findings often show limited translation into the clinic where many patients do not respond well to such treatments. The main limitation of standard pre-clinical cancer model systems, such as mono-layer cellular cultures or animal models, is the inability to reflect the intra- and inter-tumoral heterogeneity and tumor microenvironment, accepted to be major components in cancer development.
The need for pre-clinical tools that better predict the individual clinical outcome has led to the development of innovative patient-derived models. Among this new class of pre-clinical models, patient-derived xenografts (PDXs) and patient-derived organoids (PDOs) have shown great potential for guiding personalized cancer therapies as they preserve the primary molecular features exhibited in tumors.
In this Research Topic, we welcome contributions that provide original insights, novel reviews, and critical perspectives focused on, but not limited to:
- the latest developments in PDXs and PDOs as pre-clinical models
- the incorporation of cellular microenvironment in PDOs and generation of syngeneic models
- the use of PDXs and PDOs to develop and improve cancer treatments
- the ability of PDXs and PDOs models to predict the individualized treatment response
- the use of PDXs and PDOs models to study drug resistance
- the advances in the translation of PDXs and PDOs models into the clinics
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
